{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:55Z","timestamp":1792782595821,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Development Project of Jilin Province","award":["20210401174YY"],"award-info":[{"award-number":["20210401174YY"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00277-024-05813-w","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:02:35Z","timestamp":1716948155000},"page":"2455-2462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL"],"prefix":"10.1007","volume":"103","author":[{"given":"Ruiqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghe","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-2747","authenticated-orcid":false,"given":"Wenlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"3","key":"5813_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/02841860500531682","volume":"45","author":"K Ekstr\u00f6m-Smedby","year":"2006","unstructured":"Ekstr\u00f6m-Smedby K (2006) Epidemiology and etiology of non-hodgkin lymphoma\u2013a review. Acta Oncol 45(3):258\u2013271","journal-title":"Acta Oncol"},{"issue":"31","key":"5813_CR2","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","volume":"32","author":"CA Thompson","year":"2014","unstructured":"Thompson CA et al (2014) Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol 32(31):3506\u20133512","journal-title":"J Clin Oncol"},{"key":"5813_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","volume":"14","author":"R Camicia","year":"2015","unstructured":"Camicia R, Winkler HC, Hassa PO (2015) Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer 14:207","journal-title":"Mol Cancer"},{"issue":"2","key":"5813_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M et al (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87(2):146\u2013171","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10091","key":"5813_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO et al (2017) Non-hodgkin lymphoma. Lancet 390(10091):298\u2013310","journal-title":"Lancet"},{"issue":"3","key":"5813_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U et al (2017) A review of autologous stem cell transplantation in Lymphoma. Curr Hematol Malig Rep 12(3):217\u2013226","journal-title":"Curr Hematol Malig Rep"},{"issue":"23","key":"5813_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin\u2019s lymphoma. N Engl J Med 333(23):1540\u20131545","journal-title":"N Engl J Med"},{"issue":"1","key":"5813_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1634\/theoncologist.2011-0177","volume":"17","author":"A Colpo","year":"2012","unstructured":"Colpo A, Hochberg E, Chen YB (2012) Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma. Oncologist 17(1):80\u201390","journal-title":"Oncologist"},{"issue":"2","key":"5813_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/0003-4819-90-2-191","volume":"90","author":"JR Durant","year":"1979","unstructured":"Durant JR et al (1979) Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 90(2):191\u2013194","journal-title":"Ann Intern Med"},{"issue":"11","key":"5813_CR10","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","volume":"105","author":"S Bhatia","year":"2005","unstructured":"Bhatia S et al (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant Survivor Study. Blood 105(11):4215\u20134222","journal-title":"Blood"},{"issue":"1","key":"5813_CR11","doi-asserted-by":"publisher","first-page":"14071","DOI":"10.1038\/s41598-021-93516-x","volume":"11","author":"L Hahn","year":"2021","unstructured":"Hahn L et al (2021) BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy. Sci Rep 11(1):14071","journal-title":"Sci Rep"},{"issue":"3","key":"5813_CR12","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1111\/bjh.17279","volume":"192","author":"H Ghesqui\u00e8res","year":"2021","unstructured":"Ghesqui\u00e8res H et al (2021) BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres(\u2020). Br J Haematol 192(3):e94\u2013e98","journal-title":"Br J Haematol"},{"issue":"7","key":"5813_CR13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3109\/10428194.2013.842986","volume":"55","author":"E Derenzini","year":"2014","unstructured":"Derenzini E, Zinzani PL, Cheson BD (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma 55(7):1471\u20131478","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"5813_CR14","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2165\/11205860-000000000-00000","volume":"70","author":"KP Garnock-Jones","year":"2010","unstructured":"Garnock-Jones KP (2010) Bendamustine: a review of its use in the management of indolent non-hodgkin\u2019s lymphoma and mantle cell lymphoma. Drugs 70(13):1703\u20131718","journal-title":"Drugs"},{"issue":"6","key":"5813_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","volume":"93","author":"SP Chantepie","year":"2018","unstructured":"Chantepie SP et al (2018) Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol 93(6):729\u2013735","journal-title":"Am J Hematol"},{"issue":"6","key":"5813_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41409-020-0783-y","volume":"55","author":"T Hueso","year":"2020","unstructured":"Hueso T et al (2020) Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transpl 55(6):1076\u20131084","journal-title":"Bone Marrow Transpl"},{"issue":"27","key":"5813_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"3","key":"5813_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00277-016-2900-y","volume":"96","author":"S Gilli","year":"2017","unstructured":"Gilli S et al (2017) BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol 96(3):421\u2013429","journal-title":"Ann Hematol"},{"issue":"12","key":"5813_CR19","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G et al (2011) BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood 118(12):3419\u20133425","journal-title":"Blood"},{"issue":"4","key":"5813_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.clml.2013.03.009","volume":"13","author":"BM William","year":"2013","unstructured":"William BM et al (2013) Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 13(4):417\u2013423","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"5813_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB et al (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl 21(6):1046\u20131053","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05813-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T12:07:18Z","timestamp":1720094838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05813-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5813"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05813-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"18 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}